

Title (en)
ALPHA ν BETA3 INTEGRIN INHIBITORS

Title (de)
INHIBITOREN DES INTEGRINS ALPHA ν BETA3

Title (fr)
INHIBITEURS DE L'INTEGRINE ALPHA ν BETA3

Publication
EP 1206455 A1 20020522 (DE)

Application
EP 00958381 A 20000804

Priority
• DE 19939980 A 19990824
• EP 0007590 W 20000804

Abstract (en)
[origin: DE19939980A1] The invention relates to novel compounds of formula (I) which are biologically active as alpha ν beta 3 integrin ligands X-Y-Z-R<1>-CH₂-R<2>-(R<4>)-CH₂-CO-R<5>, whereby X, Y, Z, R<1>, R<2>, R<4> and R<5> have meanings cited in Claim (1). The invention also relates to the physiologically acceptable salts and solvates thereof.

IPC 1-7
C07D 213/74; **C07D 233/88**; **C07D 239/42**; **C07D 235/30**; **C07D 521/00**; **C07D 333/48**; **C07D 409/12**; **A61K 31/4184**; **A61K 31/4168**; **A61K 31/44**; **A61K 31/4402**; **A61K 31/505**; **A61P 9/10**; **A61P 35/00**

IPC 8 full level
A61K 31/4164 (2006.01); **A61K 31/4168** (2006.01); **A61K 31/4184** (2006.01); **A61K 31/44** (2006.01); **A61K 31/4402** (2006.01); **A61K 31/505** (2006.01); **A61P 7/02** (2006.01); **A61P 9/10** (2006.01); **A61P 11/00** (2006.01); **A61P 13/12** (2006.01); **A61P 17/02** (2006.01); **A61P 17/06** (2006.01); **A61P 19/10** (2006.01); **A61P 27/02** (2006.01); **C07D 233/48** (2006.01); **A61P 29/00** (2006.01); **A61P 31/00** (2006.01); **A61P 35/00** (2006.01); **A61P 43/00** (2006.01); **C07D 213/74** (2006.01); **C07D 233/60** (2006.01); **C07D 233/88** (2006.01); **C07D 235/30** (2006.01); **C07D 239/42** (2006.01)

CPC (source: EP KR US)
A61K 31/4402 (2013.01 - KR); **A61P 7/00** (2018.01 - EP); **A61P 7/02** (2018.01 - EP); **A61P 7/04** (2018.01 - EP); **A61P 9/00** (2018.01 - EP); **A61P 9/04** (2018.01 - EP); **A61P 9/06** (2018.01 - EP); **A61P 9/10** (2018.01 - EP); **A61P 11/00** (2018.01 - EP); **A61P 13/12** (2018.01 - EP); **A61P 17/00** (2018.01 - EP); **A61P 17/02** (2018.01 - EP); **A61P 17/06** (2018.01 - EP); **A61P 19/00** (2018.01 - EP); **A61P 19/02** (2018.01 - EP); **A61P 19/04** (2018.01 - EP); **A61P 19/10** (2018.01 - EP); **A61P 27/00** (2018.01 - EP); **A61P 27/02** (2018.01 - EP); **A61P 27/06** (2018.01 - EP); **A61P 27/10** (2018.01 - EP); **A61P 29/00** (2018.01 - EP); **A61P 31/00** (2018.01 - EP); **A61P 31/04** (2018.01 - EP); **A61P 31/10** (2018.01 - EP); **A61P 31/12** (2018.01 - EP); **A61P 35/00** (2018.01 - EP); **A61P 35/04** (2018.01 - EP); **A61P 43/00** (2018.01 - EP); **C07D 213/74** (2013.01 - EP KR US)

Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)
US 6645991 B1 20031111; AR 034692 A1 20040317; AU 6992500 A 20010319; BR 0013502 A 20020507; CA 2382561 A1 20010301; CN 1370146 A 20020918; CZ 2002525 A3 20020515; DE 19939980 A1 20010301; EP 1206455 A1 20020522; HK 1049667 A1 20030523; HU P0203212 A2 20030228; HU P0203212 A3 20050228; JP 2003507457 A 20030225; KR 20020086849 A 20021120; MX PA02001862 A 20021023; NO 20020885 D0 20020222; NO 20020885 L 20020222; PL 352987 A1 20030922; SK 2272002 A3 20020604; WO 0114337 A1 20010301; ZA 200202284 B 20030827

DOCDB simple family (application)
US 6918702 A 20020621; AR P000104353 A 20000823; AU 6992500 A 20000804; BR 0013502 A 20000804; CA 2382561 A 20000804; CN 00811880 A 20000804; CZ 2002525 A 20000804; DE 19939980 A 19990824; EP 0007590 W 20000804; EP 00958381 A 20000804; HK 03101817 A 20030313; HU P0203212 A 20000804; JP 2001518426 A 20000804; KR 20027001418 A 20020201; MX PA02001862 A 20000804; NO 20020885 A 20020222; PL 35298700 A 20000804; SK 2272002 A 20000804; ZA 200202284 A 20020320